ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
5.21
-0.43 (-7.62%)
At close: Oct 31, 2024, 4:00 PM
5.16
-0.05 (-0.96%)
After-hours: Oct 31, 2024, 7:31 PM EDT

Company Description

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.

Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

ImmunityBio, Inc.
ImmunityBio logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 628
CEO Richard Adcock

Contact Details

Address:
3530 John Hopkins Court
San Diego, California 92121
United States
Phone 844 696 5235
Website immunitybio.com

Stock Details

Ticker Symbol IBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326110
CUSIP Number 45256X103
ISIN Number US45256X1037
Employer ID 43-1979754
SIC Code 2836

Key Executives

Name Position
Richard Gerald Adcock President, Chief Executive Officer and Director
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. Executive Chairman of the Board and Global Chief Scientific and Medical Officer
David C. Sachs Chief Financial Officer
Dr. Barry J. Simon M.D. Chief Corporate Affairs Officer and Director
Dr. Leonard S. Sender M.D. Chief Operating Officer
Regan J. Lauer Chief Accounting Officer
Dr. Enrique Diloné Ph.D., RAC Chief Technology Officer
Jason R. Liljestrom General Counsel and Corporate Secretary
Sarah Singleton Chief Communications Officer and Head of Patient Advocacy
Dr. Sandeep K. Reddy M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Aug 12, 2024 10-Q Quarterly Report
Jul 18, 2024 8-K Current Report
Jun 20, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 12, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 2, 2024 EFFECT Notice of Effectiveness
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 29, 2024 ARS Filing
Apr 23, 2024 8-K Current Report